دورية أكاديمية
أعرض في EDS

Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade.

التفاصيل البيبلوغرافية
العنوان: Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade.
المؤلفون: Oh KY; Department of Oral Pathology, College of Dentistry, Dankook University, Cheonan, Republic of Korea.; Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea., Hong SD; Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea., Yoon HJ; Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea.
المصدر: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology [J Oral Pathol Med] 2024 Mar; Vol. 53 (3), pp. 217-225. Date of Electronic Publication: 2024 Mar 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 8911934 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0714 (Electronic) Linking ISSN: 09042512 NLM ISO Abbreviation: J Oral Pathol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford, UK : Wiley-Blackwell
Original Publication: Copenhagen : Munksgaard, c1989-
مواضيع طبية MeSH: Mouth Neoplasms*/pathology , Odontogenic Tumors*/pathology , Carcinoma*/pathology, Humans ; B7-H1 Antigen/metabolism ; Immune Checkpoint Inhibitors ; T-Lymphocytes/metabolism ; Forkhead Transcription Factors ; Tumor Microenvironment ; CD8-Positive T-Lymphocytes/pathology ; Biomarkers, Tumor
مستخلص: Background: Despite recent advances in the use of immune checkpoint blockade (ICB) across various cancer types, its efficacy in odontogenic carcinomas remains unexplored. This study aims to investigate PD-L1 expression and the tumor immune microenvironment (TIME) in odontogenic carcinomas to determine the therapeutic potential of ICB and the significance of immune markers.
Methods: The expressions of PD-L1 and T cell markers (CD3, CD8, and FOXP3) were visualized by immunohistochemistry in 21 tissue samples of odontogenic carcinomas. Tumoral PD-L1 expression and the density and spatial distribution of T cell subsets were evaluated, from which TIME was determined. The associations of the variables with clinicopathological and prognostic factors were statistically analyzed.
Results: PD-L1 was positively expressed in 52.4% (11/21) of the cases studied. Among tumor types, ameloblastic carcinoma showed significantly higher PD-L1 expression (p = 0.016). TIME based on the intratumoral and stromal T cell distribution was immune-inflamed in 61.9% (13/21) and immune-excluded in 38.1% (8/21), with no immune-desert cases. PD-L1 expression was associated with the densities of all intratumoral T cell subsets (p = 0.03 for CD3, p = 0.03 for CD8, and p = 0.008 for FOXP3) but not with those of stromal T cells. High PD-L1 expression was associated with larger tumor size (p = 0.021), while the intratumoral CD8/CD3 ratio was inversely correlated with tumor size (p = 0.048).
Conclusion: These findings indicate the involvement of adaptive immune resistance in a subset of odontogenic carcinomas and support the therapeutic potential of ICB in patients with these rare malignancies.
(© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
References: IARC. WHO Classification of Tumours Editorial Board. Head and Neck Tumours [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Nov 07]. (WHO classification of tumours series, 5th ed.; vol. 9). https://tumourclassification.iarc.who.int/chapters/52.
Oh KY. Treatment options for advanced ameloblastoma in the era of precision medicine: a brief review. Oral Oncol. 2023;146:106585.
Oh KY, Cho SD, Yoon HJ, Lee JI, Hong SD. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: comparative analysis of two VE1 antibodies. J Oral Pathol Med. 2021;50(1):85-91.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39.
Karpathiou G, Hamlat M, Dridi M, et al. Autophagy and immune microenvironment in craniopharyngioma and ameloblastoma. Exp Mol Pathol. 2021;123:104712.
Kimura M, Shiraki Y, Ishibashi K, Umemura M. Remarkable short-term regression of a posterior mediastinum metastasis from primary intraosseous carcinoma treated with Nivolumab: a case report. J Oral Maxillofac Surg. 2019;77(3):555.e551-555.e556.
Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139-2145.
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330.
Mazzaschi G, Madeddu D, Falco A, et al. Low PD-1 expression in cytotoxic CD8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res. 2018;24(2):407-419.
Hongo T, Yamamoto H, Jiromaru R, et al. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma. Mod Pathol. 2021;34(11):1966-1978.
Meagher NS, Hamilton P, Milne K, et al. Profiling the immune landscape in mucinous ovarian carcinoma. Gynecol Oncol. 2023;168:23-31.
Rooney MK, Korpics MC, Turchan WT, Callahan N, Koshy M, Spiotto MT. Patterns of care and survival outcomes for odontogenic cancers. Laryngoscope. 2021;131(5):E1496-E1502.
Vivekanandhan S, Bahr D, Kothari A, Ashary MA, Baksh M, Gabriel E. Immunotherapies in rare cancers. Mol Cancer. 2023;22(1):23.
Tray N, Weber JS, Adams S. Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application. Cancer Immunol Res. 2018;6(10):1122-1128.
Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794-801.
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-821.
Griguolo G, Dieci MV, Pare L, et al. Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. NPJ Breast Cancer. 2021;7(1):12.
Tong N, He Z, Ma Y, et al. Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor-glioma therapy? Front Cell Dev Biol. 2021;9:706286.
Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 2018;8:386.
Yadollahi P, Jeon YK, Ng WL, Choi I. Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity. BMB Rep. 2021;54(1):12-20.
Thompson ED, Taube JM, Asch-Kendrick RJ, et al. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Mod Pathol. 2017;30(11):1551-1560.
Oh KY, Hong SD, Yoon HJ. Adenoid ameloblastoma shares clinical, histologic, and molecular features with dentinogenic ghost cell tumor: the histologic spectrum of WNT pathway-altered benign odontogenic tumors. Mod Pathol. 2023;36(3):100051.
Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117(4):451-460.
Ryu HS, Park YS, Park HJ, et al. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma. Thyroid. 2014;24(8):1232-1240.
Huang Y, Lin C, Kao HK, et al. Digital image analysis of CD8+ and CD3+ tumor-infiltrating lymphocytes in tongue squamous cell carcinoma. Cancer Manag Res. 2020;12:8275-8285.
Nie H, He T, Wang L, Zhang L. Expression and prognostic value of tumor-infiltrating lymphocytes and PD-L1 in hepatocellular carcinoma. OncoTargets Ther. 2021;14:1377-1385.
Schmidt LH, Kummel A, Gorlich D, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PloS One. 2015;10(8):e0136023.
Saito H, Kono Y, Murakami Y, et al. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression. Anticancer Res. 2018;38(1):107-112.
Huang W, Ran R, Shao B, Li H. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;178(1):17-33.
معلومات مُعتمدة: RS-2023-00212868 National Research Foundation of Korea
فهرسة مساهمة: Keywords: PD-L1; immune checkpoint blockade; odontogenic carcinoma; tumor immune microenvironment
المشرفين على المادة: 0 (B7-H1 Antigen)
0 (Immune Checkpoint Inhibitors)
0 (Forkhead Transcription Factors)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240307 Date Completed: 20240319 Latest Revision: 20240319
رمز التحديث: 20240319
DOI: 10.1111/jop.13525
PMID: 38449350
قاعدة البيانات: MEDLINE
الوصف
تدمد:1600-0714
DOI:10.1111/jop.13525